Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Epstein
Richard A
RA
The University of Chicago, USA.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000068579:Celecoxib; D002839:Chromans / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007555:Isoxazoles / Q000627:therapeutic use; D007783:Lactones / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000139:chemically induced; D026706:Paternalism; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use; D000077288:Troglitazone; D014342:Truth Disclosure; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*; D014665:Vasodilator Agents / Q000627:therapeutic use; D000096926:Benzenesulfonamides
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000068579:Celecoxib; D002839:Chromans; D016861:Cyclooxygenase Inhibitors; D007004:Hypoglycemic Agents; D007555:Isoxazoles; D007783:Lactones; D010975:Platelet Aggregation Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; D045162:Thiazolidinediones; D000077288:Troglitazone; D014665:Vasodilator Agents; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides